No Data
No Data
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $45
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and Dianthus Therapeutics (DNTH)
Express News | Dianthus Therapeutics Inc: Top-Line Results Anticipated This September
Express News | Dianthus Therapeutics Completes Enrollment of Phase 2 Magic Trial of Dnth103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
Dianthus Therapeutics to Participate in Two Upcoming Investor Events